+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-Acting Insulin Analogue Market by Clinical Profile, Patient Demographics, Disease Characteristics, Administration and Dosing, Therapeutic Outcomes, Economic Impact, Healthcare Environment - Global Forecast to 2030- Product Image
Long-Acting Insulin Analogue Market by Clinical Profile, Patient Demographics, Disease Characteristics, Administration and Dosing, Therapeutic Outcomes, Economic Impact, Healthcare Environment - Global Forecast to 2030- Product Image
Sale

Long-Acting Insulin Analogue Market by Clinical Profile, Patient Demographics, Disease Characteristics, Administration and Dosing, Therapeutic Outcomes, Economic Impact, Healthcare Environment - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6159591
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Long-acting insulin analogues have redefined diabetes management by offering extended glycemic control, predictable pharmacokinetics, and fewer daily injections. As diabetes prevalence continues to rise, clinicians and patients alike seek therapeutic options that combine efficacy with convenience. These analogues have emerged as cornerstone therapies, improving adherence through reduced injection frequency and minimizing the risk of hypoglycemia via stable absorption and distribution profiles. Pharmacokinetic advances-informed by deep insights into metabolism and excretion pathways-enable more precise dosing schedules, tailoring treatment to individual needs.

In parallel, healthcare systems are grappling with cost pressures, evolving reimbursement frameworks, and shifting patient demographics. The intersection of clinical innovation and economic realities has set the stage for dynamic market shifts. Meanwhile, regulatory landscapes and tariff policies are introducing new variables that will shape supply chains and pricing strategies. This summary distills the key trends, segmentation nuances, regional dynamics, competitive forces, and strategic imperatives guiding long-acting insulin analogue development and commercialization today. With actionable recommendations for industry leaders, it paints a holistic view of how manufacturers, payers, and providers can navigate this complex environment to deliver improved patient outcomes and sustainable growth.

Transformative Shifts Redefining the Long-Acting Insulin Analogue Landscape

Rapid innovation and shifting patient expectations are driving transformative changes in the long-acting insulin analogue landscape. Advances in formulation science have extended activity profiles beyond 24 hours, reducing injection frequency and enhancing patient convenience. Precision dosing platforms are harnessing real-world data on glycemic control, adverse effects, and pharmacokinetic parameters-absorption rate, distribution, metabolism, and excretion-to optimize individualized treatment algorithms.

At the same time, digital health integration is enabling remote monitoring of efficacy measures such as reduction in HbA1c and time in range, facilitating real-time dose adjustments and patient coaching. Connected devices and smart injection pens are reshaping device preferences and injection technique, while telehealth expands access to diabetes education in home care settings.

Competing priorities in hospital settings, private clinics, and community care are prompting manufacturers to design adaptable dosing schedules and training programs. Furthermore, health economic evaluations of cost effectiveness, insurance coverage models, and market access considerations are influencing product positioning and market entry strategies. Together, these shifts underscore a more holistic, patient-centric, and data-driven approach that is redefining therapeutic outcomes and commercial success.

Assessing the Cumulative Impact of 2025 United States Tariffs

The introduction of United States tariffs in 2025 has created a ripple effect across the supply chain, impacting both raw material procurement and finished product pricing. Manufacturers sourcing global APIs face higher costs that translate into tighter margins and strategic reconsiderations of manufacturing locations. To mitigate these pressures, several organizations are evaluating increased domestic production capacity or diversifying supplier networks to include regions with favorable trade agreements.

On the distribution side, logistics expenses have risen due to both tariff-induced cost adjustments and ongoing freight volatility. Payers and providers are responding by scrutinizing product formularies and favoring analogues with demonstrable health economic benefits-particularly those that justify higher unit costs through reduced hospitalization rates and improved quality of life metrics. In parallel, market access teams are intensifying negotiations with private and public insurance payers to establish value-based contracts that share risk and reward outcomes tied to safety and efficacy measures.

Regulatory agencies have signaled openness to expedited review pathways for biosimilars and novel delivery platforms, offsetting some tariff burdens by accelerating time-to-market. In this environment, agile pricing strategies and robust pharmacoeconomic data have become essential to sustain competitive positioning.

Key Segmentation Insights Driving Market Nuances

Market segmentation reveals the multifaceted factors that determine long-acting insulin analogue adoption and performance. Clinical profile insights encompass adverse effects, dosing frequency, glycemic control, and the pharmacokinetic details of absorption rate, distribution, excretion, and metabolism, creating opportunities for targeted formulation improvements. Patient demographics play a critical role: age groups, gender, and socioeconomic strata-distinguishing between adolescents and adults-require tailored support programs and educational materials. Disease characteristics highlight distinct therapeutic pathways for Type 1 and Type 2 diabetes, calling for differentiated dosing schedules and monitoring protocols.

Administration and dosing preferences-ranging from device selection to injection technique-drive investments in user-friendly pens and smart delivery systems. Outcomes-based segmentation underscores the importance of efficacy measures such as reduction in HbA1c and time in range, while quality of life and safety outcomes inform risk-benefit assessments. Economic impact considerations include cost effectiveness, nuanced insurance coverage structures covering private and public payers, and market access hurdles in various reimbursement landscapes. Finally, the healthcare environment spans home care, hospital settings, and private clinics, each demanding customized training, support services, and supply chain logistics.

Regional Dynamics Influencing Insulin Analogue Adoption

Regional landscapes present unique opportunities and challenges for insulin analogue manufacturers. In the Americas, established reimbursement systems and high patient awareness support rapid uptake of next-generation analogues, yet competitive pricing pressures and payer demands necessitate strong pharmacoeconomic evidence. Meanwhile, in Europe, Middle East & Africa, diverse regulatory frameworks and varied healthcare investments require region-specific market access strategies, including collaborations with public insurance systems and stakeholder education programs to address urban-rural disparities.

Across Asia-Pacific, burgeoning diabetic populations, expanding private insurance coverage, and rising per capita healthcare spending are fueling demand, but infrastructure gaps in remote areas drive innovation in home care delivery models and telehealth integration. Partnerships with regional distributors and local clinical trial centers can accelerate product registration and acceptance. Together, these regional dynamics underscore the need for flexible pricing, adaptive supply chains, and targeted patient engagement initiatives to maximize adoption and improve therapeutic outcomes globally.

Competitive Landscape: Leading Companies and Strategic Movements

The competitive landscape is characterized by established leaders and emerging players forging strategic alliances and advancing technical innovations. Industry veterans such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi S.A. maintain robust portfolios, leveraging deep clinical data to defend market share. Major pharmaceutical conglomerates-Pfizer Inc., Merck & Co., Inc., Novartis International AG, and AstraZeneca PLC-are pursuing collaborations and licensing deals to enhance their injection devices and smart pen technologies.

Biosimilar specialists including Sandoz, Biocon Limited, and Mylan N.V. focus on cost-competitive alternatives, often partnering with private insurance networks to secure formulary access. Emerging entities-Cadila Healthcare Limited (Zydus Cadila), Sun Pharmaceutical Industries Ltd., and Servier Laboratories-are targeting niche markets through differentiated dosing schedules and patient support services. Device integration partnerships with Medtronic Inc., Johnson & Johnson (Janssen Pharmaceuticals), and Boston Scientific Corporation are enabling seamless dose tracking and remote monitoring.

R&D-driven companies such as Boehringer Ingelheim GmbH, Bayer AG, and Takeda Pharmaceutical Company Limited emphasize pipeline innovations in ultra-long-acting analogues and bioconjugates. Meanwhile, Roche Holding AG, Bristol Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Grifols S.A., AbbVie Inc., Allergan, Inc., Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., and UCB Pharma are actively exploring strategic mergers, portfolio expansions, and health economic partnerships to enhance their competitive positioning.

Actionable Recommendations for Industry Leaders

Industry leaders must adopt a multifaceted strategy to sustain growth and respond to evolving market dynamics. First, invest in advanced pharmacokinetic research to extend duration of action and minimize adverse effects, thereby strengthening clinical differentiation. Second, accelerate digital health initiatives by integrating smart delivery devices with patient engagement platforms, enabling real-time monitoring of reduction in HbA1c and time in range metrics. Third, optimize global supply chains by diversifying supplier networks, expanding localized manufacturing, and leveraging free trade agreements to mitigate tariff impacts.

Fourth, develop differentiated market access models by forging value-based contracts with private and public payers, aligning reimbursement with long-term therapeutic outcomes, quality of life improvements, and safety profiles. Fifth, tailor regional go-to-market strategies to address specific reimbursement frameworks in the Americas, Europe, Middle East & Africa, and Asia-Pacific, while engaging local key opinion leaders to foster adoption in both hospital settings and home care environments. Finally, pursue strategic alliances across the ecosystem-partnering with device manufacturers, telehealth providers, and contract research organizations-to accelerate innovation and enhance patient-centric support services.

Conclusion: Positioning for Sustainable Growth

The landscape of long-acting insulin analogues is more dynamic than ever, shaped by clinical innovation, tariff pressures, digital integration, and regional healthcare variations. Manufacturers that combine rigorous pharmacoeconomic evidence with adaptive pricing and market access strategies will outpace competitors. Embracing advanced delivery platforms and remote monitoring technologies will boost patient adherence and therapeutic outcomes, while diversified supply chains will protect margins against policy fluctuations.

By aligning product development with patient-centered segmentation insights-spanning clinical profiles, demographics, disease characteristics, administration preferences, outcomes metrics, economic considerations, and care settings-organizations can deliver differentiated value propositions. Strategic collaborations across the device, digital health, and contract research sectors will further accelerate time to market and deepen real-world evidence generation.

Ultimately, success hinges on an integrated approach that balances clinical differentiation with economic viability, regional agility, and a relentless focus on improving quality of life for patients with diabetes. Leaders who act decisively on these imperatives will secure sustainable growth in this rapidly evolving market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Clinical Profile
    • Adverse Effects
    • Dosing Frequency
    • Glycemic Control
    • Pharmacokinetics
      • Absorption Rate
      • Distribution
      • Excretion
      • Metabolism
  • Patient Demographics
    • Age Groups
    • Gender
    • Socioeconomic Status
      • Adolescents
      • Adults
  • Disease Characteristics
    • Type 1 Diabetes
    • Type 2 Diabetes
  • Administration and Dosing
    • Device Preferences
    • Dosing Schedules
    • Injection Technique
  • Therapeutic Outcomes
    • Efficacy Measures
      • Reduction In HbA1c
      • Time In Range
    • Quality Of Life
    • Safety Outcomes
  • Economic Impact
    • Cost Effectiveness
    • Insurance Coverage
      • Private Insurance
      • Public Insurance
    • Market Access
  • Healthcare Environment
    • Home Care
    • Hospital Settings
    • Private Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Allergan, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol Myers Squibb Company
  • Cadila Healthcare Limited (Zydus Cadila)
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Medtronic Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz
  • Sanofi S.A.
  • Servier Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-Acting Insulin Analogue Market, by Clinical Profile
8.1. Introduction
8.2. Adverse Effects
8.3. Dosing Frequency
8.4. Glycemic Control
8.5. Pharmacokinetics
8.5.1. Absorption Rate
8.5.2. Distribution
8.5.3. Excretion
8.5.4. Metabolism
9. Long-Acting Insulin Analogue Market, by Patient Demographics
9.1. Introduction
9.2. Age Groups
9.3. Gender
9.4. Socioeconomic Status
9.4.1. Adolescents
9.4.2. Adults
10. Long-Acting Insulin Analogue Market, by Disease Characteristics
10.1. Introduction
10.2. Type 1 Diabetes
10.3. Type 2 Diabetes
11. Long-Acting Insulin Analogue Market, by Administration And Dosing
11.1. Introduction
11.2. Device Preferences
11.3. Dosing Schedules
11.4. Injection Technique
12. Long-Acting Insulin Analogue Market, by Therapeutic Outcomes
12.1. Introduction
12.2. Efficacy Measures
12.2.1. Reduction In HbA1c
12.2.2. Time In Range
12.3. Quality Of Life
12.4. Safety Outcomes
13. Long-Acting Insulin Analogue Market, by Economic Impact
13.1. Introduction
13.2. Cost Effectiveness
13.3. Insurance Coverage
13.3.1. Private Insurance
13.3.2. Public Insurance
13.4. Market Access
14. Long-Acting Insulin Analogue Market, by Healthcare Environment
14.1. Introduction
14.2. Home Care
14.3. Hospital Settings
14.4. Private Clinics
15. Americas Long-Acting Insulin Analogue Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Long-Acting Insulin Analogue Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Long-Acting Insulin Analogue Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Allergan, Inc.
18.3.3. Amgen Inc.
18.3.4. AstraZeneca PLC
18.3.5. Bayer AG
18.3.6. Biocon Limited
18.3.7. Boehringer Ingelheim GmbH
18.3.8. Boston Scientific Corporation
18.3.9. Bristol Myers Squibb Company
18.3.10. Cadila Healthcare Limited (Zydus Cadila)
18.3.11. Daiichi Sankyo Company, Limited
18.3.12. Eli Lilly and Company
18.3.13. Gilead Sciences, Inc.
18.3.14. GlaxoSmithKline plc
18.3.15. Grifols S.A.
18.3.16. Johnson & Johnson (Janssen Pharmaceuticals)
18.3.17. Medtronic Inc.
18.3.18. Merck & Co., Inc.
18.3.19. Mylan N.V.
18.3.20. Novartis International AG
18.3.21. Novo Nordisk A/S
18.3.22. Pfizer Inc.
18.3.23. Roche Holding AG
18.3.24. Sandoz
18.3.25. Sanofi S.A.
18.3.26. Servier Laboratories
18.3.27. Sun Pharmaceutical Industries Ltd.
18.3.28. Takeda Pharmaceutical Company Limited
18.3.29. Teva Pharmaceutical Industries Ltd.
18.3.30. UCB Pharma
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. LONG-ACTING INSULIN ANALOGUE MARKET MULTI-CURRENCY
FIGURE 2. LONG-ACTING INSULIN ANALOGUE MARKET MULTI-LANGUAGE
FIGURE 3. LONG-ACTING INSULIN ANALOGUE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2024 VS 2030 (%)
FIGURE 18. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. LONG-ACTING INSULIN ANALOGUE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. LONG-ACTING INSULIN ANALOGUE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LONG-ACTING INSULIN ANALOGUE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADVERSE EFFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DOSING FREQUENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ABSORPTION RATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EXCRETION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY METABOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY AGE GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DEVICE PREFERENCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DOSING SCHEDULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INJECTION TECHNIQUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY REDUCTION IN HBA1C, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY TIME IN RANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY QUALITY OF LIFE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SAFETY OUTCOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COST EFFECTIVENESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PUBLIC INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY MARKET ACCESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HOSPITAL SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 82. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 83. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 84. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 86. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 87. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 88. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 89. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 90. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 91. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 92. CANADA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 93. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 99. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 100. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 101. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 102. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 139. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 140. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 141. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 142. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 143. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 144. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 145. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 146. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 147. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 148. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 149. CHINA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 150. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 151. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 152. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 153. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 154. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 155. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 156. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 157. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 158. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 159. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 160. INDIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 172. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 173. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 174. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 175. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 176. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 177. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 178. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 179. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 180. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 181. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 182. JAPAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 198. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 208. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 209. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 219. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 220. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 238. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 239. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 240. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 241. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 242. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 243. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 244. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 245. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 246. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 247. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 248. THAILAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 249. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 250. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 251. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 252. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 253. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 258. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 259. VIETNAM LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 272. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 273. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 275. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 276. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 277. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 278. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 279. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 280. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 281. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 282. DENMARK LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 283. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 284. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 285. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 286. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 287. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY DISEASE CHARACTERISTICS, 2018-2030 (USD MILLION)
TABLE 288. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ADMINISTRATION AND DOSING, 2018-2030 (USD MILLION)
TABLE 289. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY THERAPEUTIC OUTCOMES, 2018-2030 (USD MILLION)
TABLE 290. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY EFFICACY MEASURES, 2018-2030 (USD MILLION)
TABLE 291. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY ECONOMIC IMPACT, 2018-2030 (USD MILLION)
TABLE 292. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 293. EGYPT LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY HEALTHCARE ENVIRONMENT, 2018-2030 (USD MILLION)
TABLE 294. FINLAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY CLINICAL PROFILE, 2018-2030 (USD MILLION)
TABLE 295. FINLAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PHARMACOKINETICS, 2018-2030 (USD MILLION)
TABLE 296. FINLAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 297. FINLAND LONG-ACTING INSULIN ANALOGUE MARKET SIZE, BY SOCIOECONOMIC STATUS, 2018-2030 (USD MILLION)
TABLE 298

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Long-Acting Insulin Analogue market report include:
  • AbbVie Inc.
  • Allergan, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol Myers Squibb Company
  • Cadila Healthcare Limited (Zydus Cadila)
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Medtronic Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz
  • Sanofi S.A.
  • Servier Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma

Related Topics

Related Reports

Halal Insulin Market by Product Type (Analogue Insulin, Human Insulin), Patient Type (Gestational, Type 1, Type 2), Distribution Channel, End User, Route of Administration - Global Forecast 2025-2030 - Product Image

Halal Insulin Market by Product Type (Analogue Insulin, Human Insulin), Patient Type (Gestational, Type 1, Type 2), Distribution Channel, End User, Route of Administration - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Human Insulin Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product Type, Application, and End-user - Product Image

Human Insulin Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product Type, Application, and End-user

  • Report
  • 117 Pages
  • Global
From
Argentina Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Image

Argentina Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • 50 Pages
  • Argentina
From
Germany Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Image

Germany Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • 50 Pages
  • Germany
From
Brazil Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Image

Brazil Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • 50 Pages
  • Brazil
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.